Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Thomas Powles,Jonathan E. Rosenberg,Guru Sonpavde,Yohann Loriot,Ignacio Duran,Jae-Lyun Lee,Nobuaki Matsubara,Christof Vulsteke,Daniel Castellano,Chunzhang Wu,Mary Campbell,Maria Matsangou,Daniel P. Petrylak +12 more
Reads0
Chats0
TLDR
In this article, the authors showed that patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death liga...Abstract:
Background Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death liga...read more
Citations
More filters
Journal ArticleDOI
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
TL;DR: Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 as discussed by the authors .
Journal ArticleDOI
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
Richard Cathomas,Anja Lorch,Harman Maxim Bruins,Eva Compérat,Nigel C. Cowan,Jason A. Efstathiou,Rainer Fietkau,Georgios Gakis,Virginia Hernández,Estefania Linares Espinós,Yann Neuzillet,Maria J. Ribal,Matthieu Rouanne,George N. Thalmann,Antoine G. van der Heijden,Erik Veskimäe,J. Alfred Witjes,Matthew I. Milowsky +17 more
TL;DR: The updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma are presented in this paper, which provides detailed and contemporary information on the treatment of metastatic UROL cancer for incorporation into clinical practice.
Journal ArticleDOI
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
TL;DR: The updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma are presented in this paper , which provides detailed and contemporary information on the treatment of metastatic URO-LBC.
Journal ArticleDOI
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Paolo Tarantino,Paolo Tarantino,Roberto Carmagnani Pestana,Chiara Corti,Chiara Corti,Shanu Modi,Aditya Bardia,Sara M. Tolaney,Javier Cortes,Jean-Charles Soria,Giuseppe Curigliano,Giuseppe Curigliano +11 more
TL;DR: In this article, the authors summarize the current approvals of antibody-drug conjugates (ADCs) by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.
Journal ArticleDOI
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Earle F. Burgess,Mark D. Fleming,Arash Rezazadeh Kalebasty,Sergei Varlamov,Monika Joshi,Ignacio Duran,Yousef Zakharia,Sydney Akapame,Ademi Santiago-Walker,Manish Monga,Anne O'Hagan,Yohann Loriot,Scott T. Tagawa,Aude Flechon,Boris Y. Alexeev,Arash Rezazadeh,Arlene O. Siefker-Radtke,Yann Vano,Donatello Gasparro,Alketa Hamzaj,Eugeniy Kopyltsov,Jesus Gracia Donas,Begoña Mellado,Omi Parikh,Peter Schatteman,Stéphane Culine,Nadine Houede,Sylvie Zanetta,Gaetano Facchini,Giorgio V. Scagliotti,Giovanni Schinzari,Jae-Lyun Lee,Mikhail Shkolnik,Monica Joshi,Peter H. O'Donnell,Herbert Stöger,Karel Decaestecker,Luc Dirix,Jean-Pascal Machiels,Dephine Borchiellini,Remy Delva,Frederic Rolland,Boris Hadaschik,Margitta Retz,Eli Rosenbaum,Umberto Basso,Alessandra Mosca,Hyo Jin Lee,Dong Bok Shin,Cristina Cebotaru,Victor Moreno,Jose Luis Perez Gracia,Alvaro Pinto,Wen Pin Su,Shian-Shiang Wang,John D. Hainsworth,Ian D. Schnadig,Sandy Srinivas,Nicholas J. Vogelzang,Wolfgang Loidl,Johannes G. Meran,Marine Gross Goupil,Florence Joly,Florian Imkamp,Theodor Klotz,Susanne Krege,Matthias May,Wolfgang Schultze-Seemann,Arne Strauss,Uwe Zimmermann,Daniel Keizman,Avivit Peer,Avishay Sella,Rossana Berardi,Ugo De Giorgi,Cora N. Sternberg,Sun Young Rha,I. Bulat,A. O. Izmailov,Vsevolod Matveev,Vladimir Vladimirov,Joan Carles,Albert Font,Maribel Saez,Isabel Syndikus,Kathryn Tarver,Leonard Joseph Appleman,John F. Burke,Nancy A. Dawson,Sharad Jain +93 more
TL;DR: For example, Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis at median 11 months of follow-up as mentioned in this paper .
References
More filters
Journal ArticleDOI
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt,Ronald de Wit,David J. Vaughn,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Christian Heinrich Poehlein,Rodolfo F. Perini,Dean F. Bajorin +19 more
TL;DR: Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt,Christine Theodore,Tomasz Demkov,Boris Komyakov,Lisa Sengeløv,Gedske Daugaard,Armelle Caty,Joan Carles,Agnieszka Jagiełło-Gruszfeld,Oleg Karyakin,François-Michel Delgado,Patrick Hurteloup,Eric Winquist,N. Morsli,Yacine Salhi,Stéphane Culine,Hans von der Maase +16 more
TL;DR: Overall response rate, disease control, and progression-free survival were all statistically significant favoring VFL + BSC, and therefore, VFL seems to be a reasonable option for TCCU progressing after first-line platinum-based therapy.
Journal ArticleDOI
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles,Se Hoon Park,Eric Voog,Claudia Caserta,Begoña P. Valderrama,Howard Gurney,Haralabos P. Kalofonos,Siniša Radulović,Wim Demey,Anders Ullén,Yohann Loriot,Srikala S. Sridhar,Norihiko Tsuchiya,Evgeny Kopyltsov,Cora N. Sternberg,Joaquim Bellmunt,Jeanny B. Aragon-Ching,Daniel P. Petrylak,Robert J Laliberte,Jing Wang,Bo Huang,Craig Davis,Camilla Fowst,Nuno Costa,J.A. Blake-Haskins,Alessandra di Pietro,Petros Grivas +26 more
TL;DR: Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supported care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy.
Journal ArticleDOI
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Jonathan E. Rosenberg,Jonathan E. Rosenberg,Peter H. O'Donnell,Arjun Vasant Balar,Bradley Alexander McGregor,Elisabeth I. Heath,Evan Y. Yu,Evan Y. Yu,Matthew D. Galsky,Noah M. Hahn,Elaina M. Gartner,Juan Pinelli,Shang Ying Liang,Amal Melhem-Bertrandt,Daniel P. Petrylak +14 more
TL;DR: Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti–PD-1/L1 therapy.
Related Papers (5)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Elizabeth A. Burgess,Mark D. Fleming,A. Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,B. Zhong,K. Stuyckens,A. Santiago-Walker,P. De Porre,A. O'Hagan,A. Avadhani,Arlene O. Siefker-Radtke +20 more
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt,Ronald de Wit,David J. Vaughn,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Christian Heinrich Poehlein,Rodolfo F. Perini,Dean F. Bajorin +19 more
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma,Margitta Retz,Arlene O. Siefker-Radtke,Ari David Baron,Andrea Necchi,Jens Bedke,Elizabeth R. Plimack,Daniel A. Vaena,Marc-Oliver Grimm,Sergio Bracarda,Jose Angel Arranz,Sumanta K. Pal,Chikara Ohyama,Abdel Saci,Xiaotao Qu,Alexandre Lambert,Suba Krishnan,Alex Azrilevich,Matthew D. Galsky +18 more